argenx SE(NASDAQ:ARGX) 
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia...
Website: http://www.argenx.com
Founded: 2008
Full Time Employees: 186
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 575.41
H 582.72
L 553.20
C 555.11
V 547,379
10EMA 555.11
20EMA 555.11
60EMA 555.11
120EMA 555.11
250EMA 555.11